Posting of Circular

22 May 2018

AorTech International plc

("AorTech" or the "Company")

Posting of Circular

Further to its announcement on 21 May 2018, AorTech International plc (AIM: AOR), the biomaterials and medical device IP company, announces that copies of the Circular, including the Notice of General Meeting, together with the Form of Proxy and Application Form will be posted to Shareholders later today. The Circular is available on the Company's website, www.aortech.net.

Capitalised terms used in this announcement have the same meanings as in the Company's announcement of 21 May 2018.

For further information contact:

AorTech International plc Tel: +44 (0)7730 718296 

Bill Brown, Chairman

Stockdale Securities Limited Tel: +44 20 7601 6100 

Tom Griffiths/David Coaten

About AorTech:

AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.